These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26573220)

  • 21. Esomeprazole reduces gastroesophageal reflux after beer consumption in healthy volunteers.
    Franke A; Hepp C; Harder H; Beglinger C; Singer MV
    Scand J Gastroenterol; 2008; 43(12):1425-31. PubMed ID: 18924018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Control of esophageal and intragastric pH with compounded and manufactured omeprazole in patients with reflux esophagitis: a pilot study.
    Moretzsohn LD; Carvalho EB; Franco JD; Soares MP; Brito EM; Belarmino K; Coelho LG
    Can J Clin Pharmacol; 2009; 16(1):e264-72. PubMed ID: 19383986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies.
    Attwood SE; Ell C; Galmiche JP; Fiocca R; Hatlebakk JG; Hasselgren B; Långström G; Jahreskog M; Eklund S; Lind T; Lundell L
    Aliment Pharmacol Ther; 2015 Jun; 41(11):1162-74. PubMed ID: 25858519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in chirally pure proton pump inhibitors.
    Pai V; Pai N
    J Indian Med Assoc; 2007 Aug; 105(8):469-70, 472, 474. PubMed ID: 18236913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Use of omeprazole and esomeprazole in patients suffering from bronchial asthma with associated gastroesophageal reflux disease].
    Maev IV; Viuchnova ES; Balashova NN; Shchekina MI
    Eksp Klin Gastroenterol; 2003; (3):26-31, 116. PubMed ID: 14556543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study.
    Jonasson C; Tvete IF; Hatlebakk JG
    Scand J Gastroenterol; 2013 Sep; 48(9):1010-7. PubMed ID: 23859491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
    Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
    Sheu BS; Kao AW; Cheng HC; Hunag SF; Chen TW; Lu CC; Wu JJ
    Aliment Pharmacol Ther; 2005 Feb; 21(3):283-8. PubMed ID: 15691303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease].
    Sohn YH; Lee WS; Park CH; Joo YE; Kim HS; Choi SK; Rew JS; Kim SJ
    Korean J Gastroenterol; 2006 Sep; 48(3):162-71. PubMed ID: 17047431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole.
    Armstrong D; Talley NJ; Lauritsen K; Moum B; Lind T; Tunturi-Hihnala H; Venables T; Green J; Bigard MA; Mössner J; Junghard O
    Aliment Pharmacol Ther; 2004 Aug; 20(4):413-21. PubMed ID: 15298635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
    Sharma P; Johnson DA; Monyak JT; Illueca M
    Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
    Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
    Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.
    Kirchheiner J; Glatt S; Fuhr U; Klotz U; Meineke I; Seufferlein T; Brockmöller J
    Eur J Clin Pharmacol; 2009 Jan; 65(1):19-31. PubMed ID: 18925391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate.
    Choi HS; Park DI; Hwang SJ; Park JS; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI
    Helicobacter; 2007 Dec; 12(6):638-42. PubMed ID: 18001407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy and safety of esomeprazole, compared with omeprazole, in maintenance therapy for reflux esophagitis -a phase III, multicenter, randomized, double-blind trial-].
    Kinoshita Y; Miwa H; Kasugai K
    Nihon Shokakibyo Gakkai Zasshi; 2013 Aug; 110(8):1428-38. PubMed ID: 23912002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial.
    Fiocca R; Mastracci L; Attwood SE; Ell C; Galmiche JP; Hatlebakk J; Bärthel A; Långström G; Lind T; Lundell L;
    Aliment Pharmacol Ther; 2012 Nov; 36(10):959-71. PubMed ID: 22998687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and Helicobacter pylori infection in Japan.
    Muramatsu A; Azuma T; Okajima T; Ohtani M; Dojo M; Yamazaki Y; Kuriyama M
    Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 1():102-6. PubMed ID: 15298614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugs, bugs, and esophageal pH profiles.
    Robinson M
    Yale J Biol Med; 1999; 72(2-3):169-72. PubMed ID: 10780578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients.
    Davidson G; Wenzl TG; Thomson M; Omari T; Barker P; Lundborg P; Illueca M
    J Pediatr; 2013 Sep; 163(3):692-8.e1-2. PubMed ID: 23800403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reflux episodes detected by impedance in patients on and off esomeprazole: a randomised double-blinded placebo-controlled crossover study.
    Moawad FJ; Betteridge JD; Boger JA; Cheng FK; Belle LS; Chen YJ; Maydonovitch CL; Wong RK
    Aliment Pharmacol Ther; 2013 May; 37(10):1011-8. PubMed ID: 23560727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.